

08 May 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: big changes at Biogen; Paxlovid still a work in progress; Farxiga goes stellar; Moderna hints at M&A; and a chat with Roche Pharma India's CEO on rare diseases.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 6 May 2022, including: big changes at [*Biogen, Inc.*](#); Paxlovid still a work in progress; Farxiga goes stellar; [*Moderna, Inc.*](#) hints at M&A; and a chat with [*Roche Holding AG*](#) Pharma India's CEO on rare diseases.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus*](#)" - Scrip, 3 May, 2022.)

(Also see "[*Pfizer On Paxlovid: 'There's Still A Long Way To Go'*](#)" - Scrip, 3 May, 2022.)

(Also see "[*AstraZeneca's Farxiga Flies Across \\$1bn Barrier*](#)" - Scrip, 29 Apr, 2022.)

(Also see "[*Moderna Teases M&A Interest As Pandemic Expected To Wind Down*](#)" - Scrip, 4 May, 2022.)

(Also see "[*It Takes A Village: Roche's India Rare Disease Approach, Crowdfunding Support*](#)" - Scrip, 2 May, 2022.)

[Click here to explore this interactive content online](#) 